Publication:
1,2,4-Triazole Derivatives With Morpholine; DFT Study and Antileishmanial Activity

dc.authorscopusid26644545800
dc.authorscopusid8361744500
dc.authorscopusid6506730197
dc.authorscopusid28067476100
dc.authorscopusid8354984100
dc.contributor.authorSüleymanoǧlu, N.
dc.contributor.authorUstabaş, R.
dc.contributor.authorDirekel, Ş.
dc.contributor.authorAlpaslan, Y.B.
dc.contributor.authorÜnver, Y.
dc.date.accessioned2020-06-21T13:10:57Z
dc.date.available2020-06-21T13:10:57Z
dc.date.issued2018
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Süleymanoǧlu] Nevin, Technical Sciences Vocational School, Gazi Üniversitesi, Ankara, Ankara, Turkey; [Ustabaş] Reşat, Department of Mathematics and Science Education, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Direkel] Şahin, Department of Medical Microbiology, Giresun Üniversitesi, Giresun, Giresun, Turkey; [Alpaslan] Yelda Bingöl, Department of Biophysics, Giresun Üniversitesi, Giresun, Giresun, Turkey; [Ünver] Yasemin, Department of Chemistry, Karadeniz Technical University, Trabzon, Trabzon, Turkeyen_US
dc.description.abstract1,2,4-triazole derivatives with morpholine; 4-((3-methylthiophene-2-yl)methylenamino)-1-((4-(3-methylthiophene-2-yl)methylene amino)-1-(morpholinomethyl)-5-thioxo-4,5-dihydro-1H-1,2,4-triazole-3-yl)methyl)-3-(thiophene-2-ylmethyl)-1H-1,2,4-triazole-5(4H)-one (compound I) and 1-((1-(morpholinomethyl)-4-(5-nitrothiophene-2-yl)methyleneamino)-5-thioxo-4,5-dihydro-1H-1,2,4-triazole-3-yl)methyl)-4-((5-nitrothiophene-2-yl)methyleneamino)-3-(thiophene-2-ylmethyl)-1H-1,2,4-triazole-5(4H)-one (compound II), were optimized using a density functional theory (DFT) method with 6-311G(d,p) basis set and structural and spectral parameters were determined. In vitro antileishmanial activities of compounds were performed against Leishmania infantum promastigots by microdilution broth assay with Alamar Blue dye. Amphotericin B was used as standard drug. The results show that both compounds are antiparasitic and especially compound II has considerable antileishmanial activity due to the minimal inhibitory concentration value of 312 μg/mL. © 2018 Published by NRC Research Press.en_US
dc.identifier.doi10.1139/cjp-2017-0710
dc.identifier.endpage723en_US
dc.identifier.issn0008-4204
dc.identifier.issue7en_US
dc.identifier.scopus2-s2.0-85049569995
dc.identifier.scopusqualityQ3
dc.identifier.startpage719en_US
dc.identifier.urihttps://doi.org/10.1139/cjp-2017-0710
dc.identifier.volume96en_US
dc.identifier.wosWOS:000437293500012
dc.identifier.wosqualityQ3
dc.language.isoenen_US
dc.publisherCanadian Science Publishingen_US
dc.relation.ispartofCanadian Journal of Physicsen_US
dc.relation.journalCanadian Journal of Physicsen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject1,2,4-Triazoleen_US
dc.subjectAntileishmanial Activityen_US
dc.subjectDFTen_US
dc.subjectFT-IRen_US
dc.subjectNMRen_US
dc.title1,2,4-Triazole Derivatives With Morpholine; DFT Study and Antileishmanial Activityen_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files